A Study of STSA-1201 in Healthy Subjects

Healthy Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Single Ascending-Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSA-1201 Injection in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05986877
• Other study ID #: STSA-1201-01
• Status: Completed
• Phase: Phase 1
• Start date: August 4, 2023
• Est. completion date: March 14, 2024

Study information

• Verified date: August 2023
• Source: Staidson (Beijing) Biopharmaceuticals Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Phase Ia, randomized, double-blind, placebo-controlled, single dose, dose escalation safety, tolerability, and pharmacokinetic study of STSA-1201 injection in healthy subjects. A total of 44 healthy subjects were enrolled in four dosage groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: March 14, 2024
• Est. primary completion date: March 14, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy subjects, male or female, aged between 18 and 50 years, inclusive.

• Male subjects must have a weight range of 50.0 kg to 75.0 kg inclusive, and female subjects must have a weight range of 45.0 kg to 75.0 kg inclusive. All subjects must have a body mass index (BMI) of 19.0 to 26.0 kg/m^2 inclusive.

• Subjects (and their partners) must abstain from sperm/egg donation and commit to using effective methods of birth control during the trial and for 6 months post-trial.

• Subjects must have a normal or clinically acceptable medical history, physical examination, laboratory test results, chest X-ray and electrocardiogram (ECG).

• Subjects must fully understand the trial procedures, potential adverse reactions, and sign the informed consent form (ICF).

Exclusion Criteria:

• Subjects with significant clinical disorders or conditions (including but not limited to gastrointestinal, rental, liver, neurological, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular diseases) and subjects with active or suspected infections (viral, fungal, or parasitic).

• Subjects who underwent major surgery within 2 months prior to screening.

• Subjects with allergic constitution (such as allergies to two or more drugs, foods, and pollen) or potential allergy to the trial product/components.

• Subjects positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus antibody (HIV Ab) or treponema pallidum antibody (TP Ab).

• Subjects with Ig E levels exceeding the normal upper limit.

• Subjects who have smoked more than an average of 5 cigarettes per day within the 3 months prior to screening, or who are unable to abstain from using any tobacco or nicotine-containing products during the trial.

• Subjects with a history of alcohol abuse (more than 14 units per week: 1 unit of alcohol =360mL beer or 45mL spirits with 40% alcohol or 100mL wine) within the 6 months prior to screening, or unable to abstain during the trial, or failed alcohol breath test.

• Subjects with drug abuse history (morphine, ketamine, THC, methamphetamine, methylene-dioxymethamphetamine, cocaine) within 1 year prior to screening or those testing positive for urine drug abuse screening.

• Subjects who donated or lost > 400 mL blood within 3 months prior to screening, received blood transfusions or products within 4 weeks prior to enrollment, or plan to donate blood during the trial and 3 months post-trial.

• Subjects who participated in another clinical trial or received investigational drugs/vaccines within 3 months prior to screening.

• Subjects who received biologicals or monoclonal antibodies within 3 months prior to screening; subjects who used any medication (including prescription medications, over the counter medications and herbal medicines) within 14 days prior to screening; subjects previously treated with any drugs targeting thymic stromal lymphopoietin (TSLP).

• Subjects consuming xanthine-rich foods/beverages (such as coffee, strong tea, chocolate) or those that affect drug absorption, distribution, metabolism, and excretion within 48 hours prior to administration.

• Subjects who used long-acting estrogen or progestogen injections or implants within 6 months prior to screening or short-acting contraceptives within 30 days prior to the trial.

• Female subjects who test positive for serum human chorionic gonadotropin (HCG) or have abnormal HCG levels exceeding the normal upper limit.

• Female subjects who are pregnant or lactating.

• Subjects with venipuncture intolerance, history of transfusion issues, or blood/ needle-phobia.

• Subjects with any condition or circumstance which, in the opinion of the Investigator, may compromise the ability to provide informed consent, comply with the study protocol, potentially influence study outcomes, jeopardize their own safety, or any other situation deemed unsuitable for study participation by the investigator.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• STSA-1201 Subcutaneous injection
Subcutaneous injection
• Placebo
Subcutaneous injection

Locations

Country	Name	City	State
China	Beijing Shijitan Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram?Vital Signs And Physical Examination Abnormalities.	To evaluate the safety and tolerability of single subcutaneous administration of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Maximum plasma concentration (Cmax).	To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Area under the plasma concentration-time curve over a dosing interval, from time 0 to time t (AUC0-t).	To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Area under the plasma concentration-time curve from time 0 to infinity (AUC0-8).	To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Time of maximum concentration (Tmax).	To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Elimination half-life (t1/2).	To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Apparent clearance (CL/F).	To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Apparent volume of distribution (Vz/F).	To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1201 in healthy adult subjects.	Day0 through Day84
Secondary	Change from baseline in concentration of anti-drug antibody.	To evaluate the immunogenicity of STSA-1201 in healthy subjects:	Day0 through Day84